Jonah Feldman is a freelance journalist specializing in oncology. He writes for publications such as Targeted Oncology, OncLive, and Cancer Network, covering topics related to biomarker testing, novel therapies, and treatment outcomes in various types of cancer. His work has also been featured in AJMC - The American Journal of Managed Care.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Jonah Feldman's articles primarily focus on medical research, particularly in the field of oncology and hematology. His coverage heavily relies on data citation, indicating a preference for evidence-based information.
Given his emphasis on citing data, Jonah may be interested in pitches offering access to new clinical trial results or academic studies related to oncology and hematology. Additionally, he seems receptive to expert commentary from professionals involved in these fields who can provide nuanced insights into emerging treatments or therapeutic approaches.
It is important for those reaching out to Jonah Feldman with relevant pitches to ensure that the sources provided are credible experts within the healthcare and pharmaceutical industry and possess a deep understanding of the specific topics covered such as multiple myeloma, bispecific combination therapy, treatment response etc.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A review of data collected across 15 clinical centers showed that UGN-101 was effective in a broad population of patients with upper tract urothelial
By: Jonah Feldman
A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from directly sequencing the 2 agents.
Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.
By: Jonah Feldman
Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.
In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.
By: Jonah Feldman
Pembrolizumab is the first agent showing overall survival benefit as adjuvant therapy in renal cell carcinoma, leading oncologists to adopt adjuvant therapy for many of their patients.
By: Jonah Feldman
During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
By: Tony Berberabe, Jonah Feldman
While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.
By: Jordyn Sava, Jonah Feldman
RP1 with nivolumab treatment for patients with melanoma after progression on anti–PD-1 offers durable responses and a favorable safety profile, as shown in the IGNYTE study.
Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.
(833) 317-6278 
